Autoimmune hepatitis in the Alaska Native population: Autoantibody profile and HLA associations

Liver International

Volumn 34, Issue 8, 2014, Pages 1241-1249

  Ferucci, Elizabeth D ^a   Choromanski, Tammy L ^a   Hurlburt, Kathy J ^a   Livingston, Stephen ^a   Plotnik, Julia ^a   Manns, Michael P ^b   Mcmahon, Brian J ^a   James, Judith A ^c,d  

^a Liver Disease and Hepatitis Program   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Alaska native; Anti double stranded DNA antibodies; Anti Ro antibodies; Antineutrophil cytoplasmic antibodies; Autoimmune hepatitis; HLA

Indexed keywords

AUTOANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; LIVER ANTIGEN; NEUTROPHIL CYTOPLASMIC ANTIBODY; ANTINUCLEAR ANTIBODY; HLA DR3 ANTIGEN;

ADULT; ALASKA NATIVE; ALLELE; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HLA SYSTEM; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; AMERICAN INDIAN; BLOOD; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; PREVALENCE; UNITED STATES;

ALASKA; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS, AUTOIMMUNE; HLA-DR3 ANTIGEN; HUMANS; INDIANS, NORTH AMERICAN; PREVALENCE;

EID: 84905723161     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12372     Document Type: Article

References (46)

1. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002; 97: 2402-7.
2. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103.
3. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232-40.
4. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010; 25: 1681-6.
5. Minuk GY, Liu S, Kaita K, et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008; 22: 829-34.
6. Chung HV, Riley M, Ho JK, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol 2007; 21: 565-8.
7. Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol 2000; 27: 1884-91.
8. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28: 368-91.
9. Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature. Semin Arthritis Rheum 2005; 34: 662-7.
10. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-72.
11. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310-22.
12. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.
13. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 379-88.
14. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 2139-50.
15. Czaja AJ, Carpenter HA, Moore SB. HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. Dig Dis Sci 2008; 53: 522-8.
16. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
17. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
18. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 2011; 140: 1472-80.
19. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
23. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56: 2344-51.
24. Arbuckle MR, James JA, Kohlhase KF, et al. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001; 54: 211-9.
25. Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011; 63: 2396-406.
26. Bruner BF, Vista ES, Wynn DM, Harley JB, James JA. Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener's granulomatosis. Clin Exp Immunol 2010; 162: 262-70.
27. Bruner BF, Vista ES, Wynn DM, James JA. Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes. Clin Exp Immunol 2011; 164: 330-6.
28. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339-52.
29. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-4.
30. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
31. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 339-45.
32. Ferucci ED, Hurlburt KJ, Mayo MJ, et al. Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Can J Gastroenterol 2011; 25: 21-7.
33. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 208-13.
34. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis 2012; 2012: 254319.
35. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002; 47: 546-55.
36. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-68.
37. Davis P, Read AE. Antibodies to double-stranded (native) DNA in active chronic hepatitis. Gut 1975; 16: 413-5.
38. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-66.
39. Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-7.
40. Terjung B, Sohne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 808-16.
41. Wehbe AM, Johannsson B, Raife TJ, et al. Severe autoimmune neutropenia associated with acute autoimmune hepatitis. Int J Hematol 2010; 91: 673-8.
42. Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2009; 7: 98-103.
43. Richter A, Grabhorn E, Helmke K, et al. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007; 21: 427-32.
44. Hansen JA, Lanier AP, Nisperos B, Mickelson E, Dahlberg S. The HLA system in Inupiat and Central Yupik Alaskan Eskimos. Hum Immunol 1986; 16: 315-28.
45. Leffell MS, Fallin MD, Erlich HA, et al. HLA antigens, alleles and haplotypes among the Yup'ik Alaska natives: report of the ASHI Minority Workshops Part II. Hum Immunol 2002; 63: 614-25.
46. Templin DW, Boyer GS, Lanier AP, et al. Rheumatoid arthritis in Tlingit Indians: clinical characterization and HLA associations. J Rheumatol 1994; 21: 1238-44.